Blood-based detection of Alzheimer's disease may become more precise as scientists identify optimal combinations of protein markers that signal brain pathology years before symptoms emerge. This advancement could transform how millions of aging adults monitor their neurological health through simple blood tests rather than expensive brain scans. Chinese researchers analyzed blood samples from 352 participants, comparing three forms of phosphorylated tau protein (p-tau181, p-tau217, and p-tau231) both individually and in combination with beta-amyloid markers. P-tau217 demonstrated the strongest individual performance for detecting amyloid plaques in the brain, while combining any p-tau variant with beta-amyloid ratios enhanced diagnostic accuracy beyond single markers alone. The combined biomarkers showed superior correlations with brain imaging results, hippocampal shrinkage, cortical thinning, and cognitive decline patterns. These findings address a critical gap in Alzheimer's biomarker research, where the field has been uncertain whether combining multiple blood proteins meaningfully improves detection over simpler approaches. The results suggest that while p-tau217 alone performs well, strategic combinations provide incremental but meaningful improvements in identifying at-risk individuals. This represents important progress toward accessible screening tools, though the study's focus on a Chinese population and relatively modest sample size indicate broader validation is needed. The research moves the field closer to routine blood-based Alzheimer's screening that could enable earlier interventions and more precise clinical trial enrollment.